One hundred fifty-one patients with acute uncomplicated falciparum malaria were enrolled in a randomized, open-label study of oral artemether given alone for five or seven days or a sequential treatment of oral artemether followed by mefloquine. Forty patients received oral artemether, 100 mg initially, then 50 mg every 12 hr for a total dose of 500 mg over a five-day period: Group I. Fifty-eight patients received oral artemether, 100 mg initially, then 50 mg every 12 hr for a total dose of 750 mg over a seven-day period: Group II. Fifty-three patients received oral artemether, 200 mg every 8 hr for a total dose of 600 mg, followed 8 hr later with mefloquine (1,250 mg divided into two doses given 6 hr apart: Group III. All patients were admitted to the hospital for 28 days to exclude reinfection and 131 patients remained through the 28-day follow-up. Only two, nine, and nine patients in Groups I, II, and III, respectively, left the hospital prior to study completion for reasons unrelated to their treatment. Cure rates for the three groups were 74% (28 of 38) for Group I, 98% (48 of 49) for Group II, and 98% (43 of 44) for Group III. Mean fever and parasite clearance times were not significantly different (32.8, 27.5, and 31.4 hr for fever clearance times and 40.2, 40.6, and 36.7 hr for parasite clearance times of Groups I, II, and III, respectively) nor were any adverse effects seen. In vitro drug susceptibility testing of admission and recrudescent parasite isolates was conducted for 10 patients. These data showed no decreased response to artemether or dihydroartemisinin in recrudescent isolates when compared with admission isolates. The results of this study suggest that sequential treatment for two days with oral artemether (600 mg) followed by mefloquine (1,250 mg) is effective and well-tolerated in patients with acute uncomplicated falciparum malaria and may be an alternative treatment for multidrug-resistant falciparum malaria, particularly useful for treating patients in rural areas where the period of admission to the hospital should be as short as possible. A seven-day regimen of artemether alone (750 mg) is also very effective, yet requires prolonged administration of drug after malaria symptoms disappear.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4269/ajtmh.1997.56.613 | DOI Listing |
Iran J Parasitol
January 2024
Department of Internal Medicine, Marmara University Pendik Training and Research Hospital, Istanbul, Turkey.
Cureus
November 2024
Internal Medicine, Portsmouth Hospitals University, Portsmouth, GBR.
Malaria remains a significant global health challenge, particularly in endemic regions of Africa, with being the most virulent species. This case report details the presentation of a 24-year-old Caucasian woman who collapsed at a train station in the United Kingdom after experiencing a week of fever, malaise, abdominal pain, and gastrointestinal symptoms. At emergency care, she was initially resuscitated with intravenous fluids and antipyretics.
View Article and Find Full Text PDFBMC Med
November 2024
QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Background: The combination antimalarial artefenomel-piperaquine failed to achieve target efficacy in a phase 2b study in Africa and Vietnam. We retrospectively evaluated whether characterizing the pharmacological interaction of this antimalarial combination in a volunteer infection study (VIS) would have enabled prediction of the phase 2b study results.
Methods: Twenty-four healthy adults enrolled over three consecutive cohorts were inoculated with Plasmodium falciparum-infected erythrocytes on day 0.
Cureus
November 2024
Diabetes and Endocrinology, Peterborough City Hospital, Peterborough, GBR.
Gilbert's syndrome and G6PD deficiency are common genetic disorders. They both give rise to unconjugated hyperbilirubinemia through different mechanisms. Falciparum malaria-induced hemolysis is another cause of unconjugated hyperbilirubinemia.
View Article and Find Full Text PDFFront Biosci (Elite Ed)
August 2024
Faculty of Health Sciences, Centre of Excellence for Pharmaceutical Sciences (PharmacenTM), 2520 Potchefstroom, North-West, South Africa.
Background: Despite attempts to control malaria, poor drug bioavailability means malaria still places enormous pressure on health globally. It has been found that the solubility of highly lipophilic compounds can be enhanced through lipid formulations, e.g.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!